Greenwich LifeSciences' FLAMINGO-01 Trial Accelerates with 33% Screen Rate Increase, Preliminary Data Shows 80% Recurrence Reduction
GLSI has more than doubled off its 52-week low of $7.78 on light trading volume (0.3× avg).
Summary
Greenwich LifeSciences announced a significant update for its pivotal Phase III FLAMINGO-01 trial, reporting a 33% increase in the annual patient screen rate to over 800 patients per year. This acceleration is attributed to new site activations and increased patient momentum. Furthermore, the 250-patient non-HLA-A*02 arm of the trial is now fully enrolled, and preliminary analysis from this arm indicates an approximately 80% reduction in recurrence rate, trending similarly to the positive results observed in the Phase IIb trial. This progress is highly material for a clinical-stage biopharmaceutical company, as it suggests faster trial completion and strong potential efficacy for GLSI-100 in preventing breast cancer recurrence. While the company cautions that these preliminary results are not a prediction of future outcomes, the early data provides a strong positive signal. Investors will closely watch for continued enrollment progress and future, more mature data readouts from the FLAMINGO-01 trial.
At the time of this announcement, GLSI was trading at $26.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.5M. The 52-week trading range was $7.78 to $34.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.